[Effects of bradykinin in the cardiovascular effects of angiotensin-converting enzyme inhibitors]. 2002

M Galinier, and A Pathak, and C Baixas, and S Alhabaj, and V Fallouh, and J Roncali, and L Schmutz, and P Massabuau, and J M Fauvel, and J P Bounhoure
Fédération des services de cardiologie des hôpitaux, CHU de Rangueil, Toulouse 31403. galinier.m@chu-toulouse.fr

The role of bradykinin in the cardiovascular effects of angiotensin converting enzyme inhibitors remains difficult to establish. On their haemodynamic effects, bradykinin acts during their acute administration, participating in their vasodilatation action, while during their chronic administration they act slightly or not at all. On their trophic effects, the action of the tissue kallikrein-kinin system, suggested by the results of animal experimentation, is yet to be demonstrated in man. For their effects on cardiovascular morbidity and mortality the role of bradykinin remains under discussion. Nevertheless, besides ACE inhibitors, the other therapeutic agents which increase the levels of bradykinin, such as neutral endopeptidase inhibitors, have a significant field of development in the course of cardiovascular pathologies.

UI MeSH Term Description Entries
D001920 Bradykinin A nonapeptide messenger that is enzymatically produced from KALLIDIN in the blood where it is a potent but short-lived agent of arteriolar dilation and increased capillary permeability. Bradykinin is also released from MAST CELLS during asthma attacks, from gut walls as a gastrointestinal vasodilator, from damaged tissues as a pain signal, and may be a neurotransmitter. Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg,Bradykinin Acetate, (9-D-Arg)-Isomer,Bradykinin Diacetate,Bradykinin Hydrochloride,Bradykinin Triacetate,Bradykinin, (1-D-Arg)-Isomer,Bradykinin, (2-D-Pro)-Isomer,Bradykinin, (2-D-Pro-3-D-Pro-7-D-Pro)-Isomer,Bradykinin, (2-D-Pro-7-D-Pro)-Isomer,Bradykinin, (3-D-Pro)-Isomer,Bradykinin, (3-D-Pro-7-D-Pro)-Isomer,Bradykinin, (5-D-Phe)-Isomer,Bradykinin, (5-D-Phe-8-D-Phe)-Isomer,Bradykinin, (6-D-Ser)-Isomer,Bradykinin, (7-D-Pro)-Isomer,Bradykinin, (8-D-Phe)-Isomer,Bradykinin, (9-D-Arg)-Isomer,Arg Pro Pro Gly Phe Ser Pro Phe Arg
D002303 Cardiac Output, Low A state of subnormal or depressed cardiac output at rest or during stress. It is a characteristic of CARDIOVASCULAR DISEASES, including congenital, valvular, rheumatic, hypertensive, coronary, and cardiomyopathic. The serious form of low cardiac output is characterized by marked reduction in STROKE VOLUME, and systemic vasoconstriction resulting in cold, pale, and sometimes cyanotic extremities. Low Cardiac Output,Low Cardiac Output Syndrome,Output, Low Cardiac
D002320 Cardiovascular Physiological Phenomena Processes and properties of the CARDIOVASCULAR SYSTEM as a whole or of any of its parts. Cardiovascular Physiologic Processes,Cardiovascular Physiological Processes,Cardiovascular Physiology,Cardiovascular Physiological Concepts,Cardiovascular Physiological Phenomenon,Cardiovascular Physiological Process,Physiology, Cardiovascular,Cardiovascular Physiological Concept,Cardiovascular Physiological Phenomenas,Concept, Cardiovascular Physiological,Concepts, Cardiovascular Physiological,Phenomena, Cardiovascular Physiological,Phenomenon, Cardiovascular Physiological,Physiologic Processes, Cardiovascular,Physiological Concept, Cardiovascular,Physiological Concepts, Cardiovascular,Physiological Phenomena, Cardiovascular,Physiological Phenomenon, Cardiovascular,Physiological Process, Cardiovascular,Physiological Processes, Cardiovascular,Process, Cardiovascular Physiological,Processes, Cardiovascular Physiologic,Processes, Cardiovascular Physiological
D004195 Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. Animal Disease Model,Animal Disease Models,Disease Model, Animal
D006439 Hemodynamics The movement and the forces involved in the movement of the blood through the CARDIOVASCULAR SYSTEM. Hemodynamic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000806 Angiotensin-Converting Enzyme Inhibitors A class of drugs whose main indications are the treatment of hypertension and heart failure. They exert their hemodynamic effect mainly by inhibiting the renin-angiotensin system. They also modulate sympathetic nervous system activity and increase prostaglandin synthesis. They cause mainly vasodilation and mild natriuresis without affecting heart rate and contractility. ACE Inhibitor,ACE Inhibitors,Angiotensin Converting Enzyme Inhibitor,Angiotensin I-Converting Enzyme Inhibitor,Angiotensin-Converting Enzyme Inhibitor,Kininase II Inhibitor,Kininase II Inhibitors,Angiotensin I-Converting Enzyme Inhibitors,Angiotensin-Converting Enzyme Antagonists,Antagonists, Angiotensin-Converting Enzyme,Antagonists, Kininase II,Inhibitors, ACE,Inhibitors, Angiotensin-Converting Enzyme,Inhibitors, Kininase II,Kininase II Antagonists,Angiotensin Converting Enzyme Antagonists,Angiotensin Converting Enzyme Inhibitors,Angiotensin I Converting Enzyme Inhibitor,Angiotensin I Converting Enzyme Inhibitors,Antagonists, Angiotensin Converting Enzyme,Enzyme Antagonists, Angiotensin-Converting,Enzyme Inhibitor, Angiotensin-Converting,Enzyme Inhibitors, Angiotensin-Converting,II Inhibitor, Kininase,Inhibitor, ACE,Inhibitor, Angiotensin-Converting Enzyme,Inhibitor, Kininase II,Inhibitors, Angiotensin Converting Enzyme
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia

Related Publications

M Galinier, and A Pathak, and C Baixas, and S Alhabaj, and V Fallouh, and J Roncali, and L Schmutz, and P Massabuau, and J M Fauvel, and J P Bounhoure
January 1992, Journal of cardiovascular pharmacology,
M Galinier, and A Pathak, and C Baixas, and S Alhabaj, and V Fallouh, and J Roncali, and L Schmutz, and P Massabuau, and J M Fauvel, and J P Bounhoure
April 1994, Hypertension (Dallas, Tex. : 1979),
M Galinier, and A Pathak, and C Baixas, and S Alhabaj, and V Fallouh, and J Roncali, and L Schmutz, and P Massabuau, and J M Fauvel, and J P Bounhoure
January 1992, Journal of cardiovascular pharmacology,
M Galinier, and A Pathak, and C Baixas, and S Alhabaj, and V Fallouh, and J Roncali, and L Schmutz, and P Massabuau, and J M Fauvel, and J P Bounhoure
January 1993, Peptide research,
M Galinier, and A Pathak, and C Baixas, and S Alhabaj, and V Fallouh, and J Roncali, and L Schmutz, and P Massabuau, and J M Fauvel, and J P Bounhoure
January 1983, Advances in experimental medicine and biology,
M Galinier, and A Pathak, and C Baixas, and S Alhabaj, and V Fallouh, and J Roncali, and L Schmutz, and P Massabuau, and J M Fauvel, and J P Bounhoure
February 1996, European journal of pharmacology,
M Galinier, and A Pathak, and C Baixas, and S Alhabaj, and V Fallouh, and J Roncali, and L Schmutz, and P Massabuau, and J M Fauvel, and J P Bounhoure
November 1998, The American journal of cardiology,
M Galinier, and A Pathak, and C Baixas, and S Alhabaj, and V Fallouh, and J Roncali, and L Schmutz, and P Massabuau, and J M Fauvel, and J P Bounhoure
December 1993, Journal of cardiothoracic and vascular anesthesia,
M Galinier, and A Pathak, and C Baixas, and S Alhabaj, and V Fallouh, and J Roncali, and L Schmutz, and P Massabuau, and J M Fauvel, and J P Bounhoure
January 2020, Nihon yakurigaku zasshi. Folia pharmacologica Japonica,
M Galinier, and A Pathak, and C Baixas, and S Alhabaj, and V Fallouh, and J Roncali, and L Schmutz, and P Massabuau, and J M Fauvel, and J P Bounhoure
March 1997, Circulation,
Copied contents to your clipboard!